PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33416889-5 2021 Paricalcitol treatment reduced renal collagen I and renal interstitial fibrosis by decreasing the activation of the renin-angiotensin-aldosterone system through renal changes in renin, ATR1 and ATR2 mRNAs levels and renal inflammation by decreasing renal inflammatory leukocytes (CD45), ADAM17 mRNA, TGF-beta mRNA and protein and maintaining E-cadherin mRNA levels. paricalcitol 0-12 renin Homo sapiens 116-121 33416889-5 2021 Paricalcitol treatment reduced renal collagen I and renal interstitial fibrosis by decreasing the activation of the renin-angiotensin-aldosterone system through renal changes in renin, ATR1 and ATR2 mRNAs levels and renal inflammation by decreasing renal inflammatory leukocytes (CD45), ADAM17 mRNA, TGF-beta mRNA and protein and maintaining E-cadherin mRNA levels. paricalcitol 0-12 renin Homo sapiens 178-183 33416889-7 2021 CONCLUSIONS: Paricalcitol effectively attenuated the renal interstitial fibrosis induced by CRF through a combination of inhibitory actions on the renin-angiotensin-aldosterone system, inflammation and epithelial/mesenchymal transition. paricalcitol 13-25 renin Homo sapiens 147-152 29715294-0 2018 Correction: Treatment combining aliskiren with paricalcitol is effective against progressive renal tubulointerstitial fibrosis via dual blockade of intrarenal renin. paricalcitol 47-59 renin Homo sapiens 159-164 19946310-4 2009 Paricalcitol inhibited renin transcription, countering the compensatory ACEI-induced rise in renin, thus achieving a more complete blockade of the renin-angiotensin system (RAS). paricalcitol 0-12 renin Homo sapiens 23-28 23926179-3 2013 We hypothesized that calcitriol and paricalcitol would increase plasma renin activity (PRA) independently of plasma Ca(2+) via hypercalciuria-mediated polyuria, hypovolemia, and subsequent increased beta-adrenergic sympathetic activity. paricalcitol 36-48 renin Homo sapiens 71-76 23167771-0 2012 Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study. paricalcitol 33-45 renin Homo sapiens 100-105 22169009-9 2012 In cultured podocytes, paricalcitol and calcitriol at concentrations in the physiological and clinically significant range prevented the increase in MCP-1, IL-6, renin, and fibronectin mRNA expression and the secretion of MCP-1 to the culture media induced by high glucose. paricalcitol 23-35 renin Homo sapiens 162-167 21561543-3 2011 Paricalcitol appears also to block the renin-angiotensin-aldosterone system. paricalcitol 0-12 renin Homo sapiens 39-44 19946310-4 2009 Paricalcitol inhibited renin transcription, countering the compensatory ACEI-induced rise in renin, thus achieving a more complete blockade of the renin-angiotensin system (RAS). paricalcitol 0-12 renin Homo sapiens 93-98 19946310-4 2009 Paricalcitol inhibited renin transcription, countering the compensatory ACEI-induced rise in renin, thus achieving a more complete blockade of the renin-angiotensin system (RAS). paricalcitol 0-12 renin Homo sapiens 93-98